-
Like two trains steaming full-speed toward each other, the growing aging population and the continuing shortage of nurses and other providers threaten to come crashing together, derailing whatever progress hospices make toward increasing access to their services.
-
The number of terminally ill patients enrolled in Americas hospices continues to rise, now topping 700,000 per year. But growth in patient enrollment has been counterbalanced in recent years by declining lengths of stay. The net result for many hospices has been stagnating average daily census, a more telling measure of actual growth.
-
Another study about how palliative care fails minorities was recently released, adding to what seems like mounting evidence that hospice and others involved in end-of-life care are failing to meet the needs of African-Americans, including understanding the cultural factors that play a role in patients perception of pain.
-
-
Nearly as quickly as 21st century technology is creating a new problem in the HIV/AIDS epidemic, the same technology offers a solution.
-
Recent studies of the rapid HIV tests use among at-risk populations show that the test can be a valuable tool when combined with counseling in intervention programs because the percentage of people who stay to receive their test results is very high.
-
Successful Internet prevention programs need to reach the population most at risk for HIV and which uses the Internet as a major avenue for meeting anonymous sexual partners.
-
A recent study of student behavior in high schools where condoms are available suggests that the mere fact of having condoms in schools does not increase sexual behavior among students.1
-
As if AIDS Drug Assistance Program (ADAP) directors and other people monitoring the costs of providing HIV drugs to the uninsured werent worried enough, they have a new potential problem to discuss: How would t he states and ADAP programs handle a large influx of new HIV and AIDS patients if the Centers for Disease Control and Prevention (CDC) succeeds in significantly increasing HIV testing rates?
-
The Food and Drug Administration has approved Emtriva (FTC, emtricitabine), a new nucleoside reverse transcriptase inhibitor (NRTI) to be used in combination with other antiretroviral agents.
